Table 3.

Discrepant metabolites identified by GC-TOF/MS analysis between early-stage NSCLC patients and HC.

Peak	Similarity	Metabolite	VIP	Fold-change
1	326	3-(2-Hydroxyphenyl)propionic acid	1.50	0.81
2	279	4-Acetylbutyric acid 2	1.56	1.32
3	291	Galactonic acid	4.26	6.64
4	523	Ethanolamine	1.32	0.88
5	326	4-Androsten-19-ol-3,17-dione 1	3.67	11.59
6	789	2-Hydroxypyridine	1.10	0.83
7	814	Mannose 2	1.59	1.74
8	378	2-Deoxyerythritol	1.30	0.83
9	582	Sedoheptulose	1.28	0.77
10	780	Isoleucine	1.37	0.74
11	783	D-(glycerol-1-phosphate)	2.91	1.90
12	380	3-Hydroxybutyric acid	3.29	1.60
13	777	Aspartic acid 1	1.21	0.76
14	649	β-Glycerophosphoric acid	1.39	0.87
15	264	Prostaglandin E2 2	1.06	1.68
16	607	Glucose-1-phosphate	1.52	0.82
17	410	P-cresol	1.17	0.60
18	676	4-Aminobutyric acid 3	1.24	0.67
19	363	Lyxose 1	1.45	0.85